Table 1.
Total patient group
(N = 146) |
Patient group with follow-up data
(N = 100) |
||
---|---|---|---|
Baseline data | Baseline data | Follow-up data | |
Demographics | |||
Age; years, mean (SD) | 48.30 (11.16) | 48.40 (10.97) | 53.00 (10.84) |
Women; n (%) | 98 (67.1) | 69 (69.0) | 69 (69.0) |
Education; median (range) | 4 (1–7) | 4 (1–7) | 4.5 (1–7) |
Clinical characteristics | |||
MS type; RRMS/SPMS/PPMS (%) | 76.6/12.4/11.0 | 80.0/13.0/7.0 | 69.0/23.0/7.0 |
Disease duration; years, mean (SD) | 12.95 (7.74) | 13.17 (7.48) | 17.77 (7.32) |
EDSS; median (range) | 3 (0–8) | 3 (0–8) | 4 (0–8.5) |
Cognitive scores, mean (SD) | Z-score | Z-score | Yearly rate of cognitive change |
SRT—Verbal memory | −0.72 (1.14) | −0.77 (1.18) | −0.08 (0.24) |
10/36 SPART-Visuospatial memory | −1.02 (1.26) | −1.01 (1.28) | −0.01 (0.27) |
SDMT—Information processing speed | −1.46 (1.20) | −1.40 (1.18) | −0.04 (0.21) |
MCT—Working memory | −1.33 (1.43) | −1.37 (1.48) | −0.03 (0.30) |
WLGT—Verbal fluency | −0.81 (0.91) | −0.76 (0.86) | −0.04 (0.19) |
CST—Executive function | −1.12 (1.42) | −0.99 (1.35) | −0.08 (0.27) |
SCWT—Sustained attention and executive function | −0.94 (1.05) | −0.93 (1.10) | 0.05 (0.25) |
Average cognition | −1.07 (0.80) | −1.03 (0.80) | −0.03 (0.11) |
MRI characteristics | |||
Deep gray matter volume; mL, mean (SD) | 55.79 (6.39) | 56.37 (6.27) | — |
Cortical gray matter volume; L, mean (SD) | 0.70 (0.05) | 0.75 (0.06) | — |
White matter lesion volume; mL, median (range) | 10.04 (1.36–85.5) | 8.56 (1.36–69.18) | — |
SD: standard deviation; MS: multiple sclerosis; RRMS: relapsing remitting multiple sclerosis; SPMS: secondary progressive multiple sclerosis. PPMS: primary progressive multiple sclerosis; EDSS: Expanded Disability Status Scale; SRT: Selective Reminding Test; SPART: Spatial Recall Test; SDMT: Symbol Digit Modalities Test; MCT: Memory Comparison Test; WLGT: Word List Generation Test; CST: Concept Shifting Test; SCWT: Stroop Color-Word Test; MRI: magnetic resonance imaging.
Disease duration represents the disease duration since symptom onset.